<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">38088242</PMID><DateCompleted><Year>2024</Year><Month>03</Month><Day>13</Day></DateCompleted><DateRevised><Year>2024</Year><Month>03</Month><Day>13</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1365-2362</ISSN><JournalIssue CitedMedium="Internet"><Volume>54</Volume><Issue>4</Issue><PubDate><Year>2024</Year><Month>Apr</Month></PubDate></JournalIssue><Title>European journal of clinical investigation</Title><ISOAbbreviation>Eur J Clin Invest</ISOAbbreviation></Journal><ArticleTitle>Circulating haematopoietic stem cells and long-term outcomes of COVID-19.</ArticleTitle><Pagination><StartPage>e14150</StartPage><MedlinePgn>e14150</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1111/eci.14150</ELocationID><Abstract><AbstractText Label="BACKGROUND AND AIMS" NlmCategory="OBJECTIVE">An acute depletion of circulating haematopoietic stem/progenitor cells (HSPCs) occurs during COVID-19, especially among patients with a poorer disease course. We herein examined whether HSPCs levels at hospital admission for COVID-19 predict 1-year mortality and the long-COVID syndrome.</AbstractText><AbstractText Label="MATERIALS AND METHODS" NlmCategory="METHODS">Patients hospitalized for COVID-19 in an infectious disease ward were consecutively enrolled. Circulating HSPC levels were assessed by flow cytometry as cells expressing CD34 and/or CD133. Follow-up was performed for 12&#x2009;months after hospitalization through the review of electronic medical records and demographic local registers.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">The study included 100 patients, 36 of whom reported symptoms of long-COVID and 20 died during follow-up. The reduction of 1-SD of HSPCs was associated with a 3- to 5-fold increase in the risk of 1-year mortality. Age, admission hyperglycaemia, C-reactive protein peak, liver enzymes, the need of high-flow oxygen and/or invasive ventilation were predictors of mortality at univariate analysis. Among pre-existing comorbidities, coronary heart disease and chronic kidney disease, but not diabetes, were associated with 1-year mortality. In multivariate analyses, HSPCs remained significantly associated with 1-year mortality independently of confounders. The development of pneumonia an in-hospital treatment with glucocorticoids and convalescent plasma were associated with long-COVID symptoms at follow-up. HSPCs, diabetes and other comorbidities were not predictors of long-COVID.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">In a cohort of patients hospitalized for COVID-19, lower HSPC levels at the time of admission were independent predictors of 1-year mortality. However, COVID-19 severity, but not HSPC level, was significantly associated with the development of long-COVID symptoms.</AbstractText><CopyrightInformation>&#xa9; 2023 The Authors. European Journal of Clinical Investigation published by John Wiley &amp; Sons Ltd on behalf of Stichting European Society for Clinical Investigation Journal Foundation.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Bonora</LastName><ForeName>Benedetta Maria</ForeName><Initials>BM</Initials><Identifier Source="ORCID">0000-0002-6770-2723</Identifier><AffiliationInfo><Affiliation>Department of Medicine, University Hospital of Padova, Padua, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Veneto Institute of Molecular Medicine, Padua, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Marassi</LastName><ForeName>Marella</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Medicine, University Hospital of Padova, Padua, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fogar</LastName><ForeName>Paola</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Medicine, University Hospital of Padova, Padua, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zuin</LastName><ForeName>Jenny</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Medicine, University Hospital of Padova, Padua, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cappellari</LastName><ForeName>Roberta</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Medicine, University Hospital of Padova, Padua, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Marinello</LastName><ForeName>Serena</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Medicine, University Hospital of Padova, Padua, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ferrari</LastName><ForeName>Anna</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Medicine, University Hospital of Padova, Padua, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cattelan</LastName><ForeName>Annamaria</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Medicine, University Hospital of Padova, Padua, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Avogaro</LastName><ForeName>Angelo</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Medicine, University Hospital of Padova, Padua, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Basso</LastName><ForeName>Daniela</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Medicine, University Hospital of Padova, Padua, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fadini</LastName><ForeName>Gian Paolo</ForeName><Initials>GP</Initials><AffiliationInfo><Affiliation>Department of Medicine, University Hospital of Padova, Padua, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Veneto Institute of Molecular Medicine, Padua, Italy.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><Agency>Fondazione Cassa di Risparmio di Padova e Rovigo</Agency><Country/></Grant><Grant><GrantID>202077EYN7</GrantID><Agency>Italian Ministry of Education University and Research</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>12</Month><Day>13</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Eur J Clin Invest</MedlineTA><NlmUniqueID>0245331</NlmUniqueID><ISSNLinking>0014-2972</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000094024" MajorTopicYN="N">Post-Acute COVID-19 Syndrome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000093522" MajorTopicYN="N">COVID-19 Serotherapy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006760" MajorTopicYN="N">Hospitalization</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006412" MajorTopicYN="N">Hematopoietic Stem Cells</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003920" MajorTopicYN="Y">Diabetes Mellitus</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">SARS-CoV-2</Keyword><Keyword MajorTopicYN="N">outcome</Keyword><Keyword MajorTopicYN="N">stem cells</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="revised"><Year>2023</Year><Month>11</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>10</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>11</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>3</Month><Day>13</Day><Hour>6</Hour><Minute>46</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>12</Month><Day>13</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>12</Month><Day>13</Day><Hour>5</Hour><Minute>33</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">38088242</ArticleId><ArticleId IdType="doi">10.1111/eci.14150</ArticleId></ArticleIdList><ReferenceList><Title>REFERENCES</Title><Reference><Citation>WHO. Coronavirus (COVID-19) dashboard. https://covid19.who.int/</Citation></Reference><Reference><Citation>Nalbandian A, Sehgal K, Gupta A, et&#xa0;al. Post-acute COVID-19 syndrome. Nat Med. 2021;27:601-615. doi:10.1038/s41591-021-01283-z</Citation></Reference><Reference><Citation>Davis HE, McCorkell L, Vogel JM, Topol EJ. Long COVID: major findings, mechanisms and recommendations. Nat Rev Microbiol. 2023;21:133-146. doi:10.1038/s41579-022-00846-2</Citation></Reference><Reference><Citation>National Institute for Health and Care Excellence (NICE). COVID-19 rapid guideline: managing the long-term effects of COVID-19. 2021. https://www.nice.org.uk/guidance/ng188/</Citation></Reference><Reference><Citation>Subramanian A, Nirantharakumar K, Hughes S, et&#xa0;al. Symptoms and risk factors for long COVID in non-hospitalized adults. Nat Med. 2022;28:1706-1714. doi:10.1038/s41591-022-01909-w</Citation></Reference><Reference><Citation>Maglietta G, Diodati F, Puntoni M, et&#xa0;al. Prognostic factors for post-COVID-19 syndrome: a systematic review and meta-analysis. J Clin Med. 2022;11:1541. doi:10.3390/jcm11061541</Citation></Reference><Reference><Citation>Thompson EJ, Williams DM, Walker AJ, et&#xa0;al. Long COVID burden and risk factors in 10 UK longitudinal studies and electronic health records. Nat Commun. 2022;13:3528. doi:10.1038/s41467-022-30836-0</Citation></Reference><Reference><Citation>Iwasaki A, Putrino D. Why we need a deeper understanding of the pathophysiology of long COVID. Lancet Infect Dis. 2023;23:393-395. doi:10.1016/S1473-3099(23)00053-1</Citation></Reference><Reference><Citation>Welner RS, Kincade PW. Stem cells on patrol. Cell. 2007;131:842-844. doi:10.1016/j.cell.2007.11.010</Citation></Reference><Reference><Citation>Ballard VLT, Edelberg JM. Stem cells and the regeneration of the aging cardiovascular system. Circ Res. 2007;100:1116-1127. doi:10.1161/01.RES.0000261964.19115.e3</Citation></Reference><Reference><Citation>Fadini GP, Boscaro E, de Kreutzenberg S, et&#xa0;al. Time course and mechanisms of circulating progenitor cell reduction in the natural history of type 2 diabetes. Diabetes Care. 2010;33:1097-1102. doi:10.2337/dc09-1999</Citation></Reference><Reference><Citation>Fadini GP, de Kreutzenberg SV, Coracina A, et&#xa0;al. Circulating CD34+ cells, metabolic syndrome, and cardiovascular risk. Eur Heart J. 2006;27:2247-2255. doi:10.1093/eurheartj/ehl198</Citation></Reference><Reference><Citation>Bonora BM, Palano MT, Testa G, et&#xa0;al. Hematopoietic progenitor cell liabilities and alarmins S100A8/A9-related inflammaging associate with frailty and predict poor cardiovascular outcomes in older adults. Aging Cell. 2022;21:e13545. doi:10.1111/acel.13545</Citation></Reference><Reference><Citation>Rigato M, Bittante C, Albiero M, Avogaro A, Fadini GP. Circulating progenitor cell count predicts microvascular outcomes in type 2 diabetic patients. J Clin Endocrinol Metab. 2015;100:2666-2672. doi:10.1210/jc.2015-1687</Citation></Reference><Reference><Citation>Fadini GP, Rigato M, Cappellari R, Bonora BM, Avogaro A. Long-term prediction of cardiovascular outcomes by circulating CD34+ and CD34+CD133+ stem cells in patients with type 2 diabetes. Diabetes Care. 2017;40:125-131. doi:10.2337/dc16-1755</Citation></Reference><Reference><Citation>Fadini GP, Mehta A, Dhindsa DS, et&#xa0;al. Circulating stem cells and cardiovascular outcomes: from basic science to the clinic. Eur Heart J. 2019;41:4271-4282. doi:10.1093/eurheartj/ehz923</Citation></Reference><Reference><Citation>Bonora BM, Fogar P, Zuin J, et&#xa0;al. Hyperglycemia, reduced hematopoietic stem cells, and outcome of COVID-19. Diabetes. 2022;71:788-794. doi:10.2337/db21-0965</Citation></Reference><Reference><Citation>Knight SR, Ho A, Pius R, et&#xa0;al. Risk stratification of patients admitted to hospital with covid-19 using the ISARIC WHO clinical characterisation protocol: development and validation of the 4C mortality score. BMJ. 2020;370:m3339. doi:10.1136/bmj.m3339</Citation></Reference><Reference><Citation>Kostakis I, Smith GB, Prytherch D, et&#xa0;al. The performance of the National Early Warning Score and National Early Warning Score 2 in hospitalised patients infected by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Resuscitation. 2021;159:150-157. doi:10.1016/j.resuscitation.2020.10.039</Citation></Reference><Reference><Citation>Fadini GP, Morieri ML, Boscari F, et&#xa0;al. Newly-diagnosed diabetes and admission hyperglycemia predict COVID-19 severity by aggravating respiratory deterioration. Diabetes Res Clin Pract. 2020;168:108374. doi:10.1016/j.diabres.2020.108374</Citation></Reference><Reference><Citation>Ben Nasr M, D'Addio F, Montefusco L, et&#xa0;al. Indirect and direct effects of SARS-CoV-2 on human pancreatic islets. Diabetes. 2022;71:1579-1590. doi:10.2337/db21-0926</Citation></Reference><Reference><Citation>Montefusco L, Ben Nasr M, D'Addio F, et&#xa0;al. Acute and long-term disruption of glycometabolic control after SARS-CoV-2 infection. Nat Metab. 2021;3:774-785. doi:10.1038/s42255-021-00407-6</Citation></Reference><Reference><Citation>Ratajczak MZ, Bujko K, Ciechanowicz A, et&#xa0;al. SARS-CoV-2 entry receptor ACE2 is expressed on very small CD45(&#x2212;) precursors of hematopoietic and endothelial cells and in response to virus spike protein activates the Nlrp3 Inflammasome. Stem Cell Rev Reports. 2021;17:266-277. doi:10.1007/s12015-020-10010-z</Citation></Reference><Reference><Citation>Ropa J, Cooper S, Capitano ML, Van't Hof W, Broxmeyer HE. Human hematopoietic stem, progenitor, and immune cells respond ex&#xa0;vivo to SARS-CoV-2 spike protein. Stem Cell Rev Reports. 2021;17:253-265. doi:10.1007/s12015-020-10056-z</Citation></Reference><Reference><Citation>Kucia M, Ratajczak J, Bujko K, et&#xa0;al. An evidence that SARS-Cov-2/COVID-19 spike protein (SP) damages hematopoietic stem/progenitor cells in the mechanism of pyroptosis in Nlrp3 inflammasome-dependent manner. Leukemia. 2021;35:3026-3029. doi:10.1038/s41375-021-01332-z</Citation></Reference><Reference><Citation>Wang X, Wen Y, Xie X, et&#xa0;al. Dysregulated hematopoiesis in bone marrow marks severe COVID-19. Cell Discov. 2021;7:1-18. doi:10.1038/s41421-021-00296-9</Citation></Reference><Reference><Citation>Albiero M, Ciciliot S, Tedesco S, et&#xa0;al. Diabetes-associated Myelopoiesis drives stem cell Mobilopathy through an OSM-p66Shc signaling pathway. Diabetes. 2019;68:1303-1314. doi:10.2337/db19-0080</Citation></Reference><Reference><Citation>Ratajczak MZ, Kucia M. SARS-CoV-2 infection and overactivation of Nlrp3 inflammasome as a trigger of cytokine &#x2018;storm&#x2019; and risk factor for damage of hematopoietic stem cells. Leukemia. 2020;34:1726-1729. doi:10.1038/s41375-020-0887-9</Citation></Reference><Reference><Citation>Elahi S. Hematopoietic responses to SARS-CoV-2 infection. Cell Mol Life Sci. 2022;79:187. doi:10.1007/s00018-022-04220-6</Citation></Reference><Reference><Citation>Harding JL, Oviedo SA, Ali MK, et&#xa0;al. The bidirectional association between diabetes and long-COVID-19 - a systematic review. Diabetes Res Clin Pract. 2023;195:110202. doi:10.1016/j.diabres.2022.110202</Citation></Reference><Reference><Citation>Sudre CH, Murray B, Varsavsky T, et&#xa0;al. Attributes and predictors of long COVID. Nat Med. 2021;27:626-631. doi:10.1038/s41591-021-01292-y</Citation></Reference><Reference><Citation>Jiang DH, Roy DJ, Gu BJ, Hassett LC, McCoy RG. Postacute sequelae of severe acute respiratory syndrome coronavirus 2 infection: a state-of-the-art review. JACC Basic to Transl Sci. 2021;6:796-811. doi:10.1016/j.jacbts.2021.07.002</Citation></Reference><Reference><Citation>Loretelli C, Abdelsalam A, D'Addio F, et&#xa0;al. PD-1 blockade counteracts post-COVID-19 immune abnormalities and stimulates the anti-SARS-CoV-2 immune response. JCI Insight. 2021;6:e146701. doi:10.1172/jci.insight.146701</Citation></Reference><Reference><Citation>Munblit D, O'Hara ME, Akrami A, Perego E, Olliaro P, Needham DM. Long COVID: aiming for a consensus. Lancet Respir Med. 2022;10:632-634. doi:10.1016/S2213-2600(22)00135-7</Citation></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>